GW Pharma soars as CBD-based drug a step closer to commercial launch
This announcement “renders the launch set-up fairly straightforward for GW into a market where there is significant unmet medical need and very high pent up awareness/demand,” wrote Stifel analyst Paul Mattela. “We continue to recommend […]